Brain Orthotopic Xenograft

Reagents and chemicals

• Sterile cell-suspension vehicle is used to deliver viable tumor cells intracranially, and D-luciferin is used when firefly-luciferase-expressing tumor cells are monitored by bioluminescence imaging^[1][4][7].

• Contrast agents are used when MRI, micro-CT, or clinical CT is selected for anatomic tumor-volume measurement, and contrast-enhanced imaging has been used to compare intracranial tumor volume with histology or bioluminescence imaging^[5][6].

Antibodies, probes, dyes, or kits

• Firefly luciferase, near-infrared fluorescent proteins, far-red fluorescent proteins, or dual fluorescent/bioluminescent reporters are used to monitor intracranial tumor growth in living animals and in excised tissue^{[2][3][4][7][8]}.

• H&E staining and immunohistochemistry are used to confirm intracranial tumor formation, assess tumor histology, and compare xenograft features with the original patient tumor when patient-derived xenografts are used^[2][3][8].

Equipment and instruments

• A stereotactic frame, cranial drill or burr-hole equipment, microsyringe or Hamilton syringe, anesthesia system, surgical microscope or magnification, warming support, and postoperative monitoring setup are used for intracranial implantation^[1][7].

• An in vivo imaging system, fluorescence molecular tomography platform, MRI, micro-CT, clinical CT, or histology workflow is used depending on whether the study measures optical signal, anatomic tumor volume, or tissue-level tumor burden^[4][5][6][8].

Preparation Steps

• Use immunodeficient mice for human glioblastoma cell-line xenografts or patient-derived xenografts, and use matched experimental groups with the same tumor-cell preparation, implantation site, and monitoring schedule^[1][2][3].

• Prepare tumor cells or patient-derived tumor material as a viable suspension or spheroid preparation, confirm reporter expression when optical imaging is planned, and use consistent implantation conditions because tumor growth measurements depend on cell preparation, engraftment efficiency, and imaging modality^[1][2][4][8].

Operation Steps

• Anesthetize the mouse, secure the head in a stereotactic frame, expose the skull, create a burr hole at the selected stereotactic coordinate, inject the tumor-cell suspension slowly into the target brain region, withdraw the needle carefully, close the cranial opening and skin incision, and monitor recovery under the approved animal protocol^[1][7].

• After implantation, monitor tumor growth longitudinally using the selected imaging method; bioluminescence imaging provides repeated functional tumor tracking in luciferase models, while MRI and CT provide anatomic tumor-volume information and can complement optical imaging^[1][4][5][6].

• At endpoint or humane endpoint, collect the brain for ex vivo imaging and histology, and evaluate tumor location, tumor volume, invasion, necrosis, vascularity, proliferation, or biomarker preservation according to the study question^[2][3][5][8].

Data Acquisition and Analysis

• Successful implantation is indicated by detectable intracranial tumor signal or tumor mass at the expected brain site, followed by progressive signal or volume increase and histologic confirmation of tumor tissue^[1][4][5][7].

• Bioluminescence signal should be interpreted as a longitudinal surrogate of viable reporter-expressing tumor burden, while MRI, CT, and histology provide complementary structural or tissue-level validation because optical signal and anatomic volume can diverge depending on tumor biology and imaging conditions^[4][5][6].

• Use vehicle-only or sham-implanted controls when procedure-related effects are relevant, use a known tumorigenic cell line or validated PDX as a positive engraftment control, randomize animals before treatment studies, and blind histologic or imaging-volume analysis when feasible^[1][4][5][6].

Problem: No intracranial tumor signal or low engraftment.

• Possible Cause: Poor tumor-cell viability, weak reporter expression, inadequate implantation accuracy, or model-specific engraftment failure.
• Literature-supported Solution: Confirm viable reporter-positive cells before implantation, use a validated stereotactic implantation method, and confirm tumor formation by histology or anatomic imaging rather than relying on optical signal alone^[1][2][4][7].

Problem: Optical signal does not match tumor volume.

• Possible Cause: Bioluminescence reflects viable reporter-expressing cells and substrate-dependent signal, whereas MRI, CT, and histology measure anatomic or tissue-level tumor burden.
• Literature-supported Solution: Use complementary imaging or histologic validation when quantitative tumor burden is critical^[4][5][6].

Problem: Tumor localization is inconsistent.

• Possible Cause: Stereotactic targeting or injection technique varies between animals.
• Literature-supported Solution: Use a stereotactic frame, standardized cranial coordinates, controlled injection technique, and endpoint histology to verify injection-site tumor growth^[1][7].